New Weight-Loss drug versions put to the test
NCT ID NCT07605052
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This study tests two different versions of the drug cagrilintide in 50 adults with overweight or obesity. Participants will receive injections of either version B or D for about 14 weeks to compare how the drug behaves in the body. The goal is to find which version works best for weight control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion, Phoenix
Tempe, Arizona, 85283, United States
Conditions
Explore the condition pages connected to this study.